Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cardiovascular drug use and the incidence of erectile dysfunction

International Journal of Impotence Research volume 19, pages 208–212 (2007)Cite this article

Abstract

It is unclear whether high blood pressure per se or antihypertensive drug use causes erectile dysfunction (ED). The aim of this study was to investigate the effect of cardiovascular diseases and their concomitant medications use on the incidence of ED. The target population consisted of men aged 55, 65 or 75 years old residing in the study area in Finland in 1999. Questionnaires were mailed to 2837 men in 1999 and to 2510 of them 5 years later. The follow-up sample consisted of 1665 men (66% of those eligible) who responded to both baseline and follow-up questionnaires. Men free of moderate or severe ED at baseline (N=1000) were included in the study. ED was assessed by two questions on subject ability to achieve or maintain an erection sufficient for intercourse. Poisson regression model was used in the multivariable analyses. The risk of ED was higher in men suffering from treated hypertension or heart disease than in those with the untreated condition. The risk of ED was higher in men using calcium channel inhibitor (adjusted relative risk (RR)=1.6, 95% confidence interval (CI) 1.0–2.4), angiotensin II antagonist (RR=2.2, 95% CI 1.0–4.7), non-selective β-blocker (RR=1.7, 95% CI 0.9–3.2) or diuretic (RR=1.3, CI 0.7–2.4) compared with non-users. ED was not associated with using organic nitrates, angiotensin-converting enzyme inhibitors, selective β-blockers and serum lipid-lowering agents. In summary, calcium channel inhibitors, angiotensin II antagonists, non-selective β-blockers and diuretics may increase the risk of ED.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB . Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61.

    Article  CAS  Google Scholar 

  2. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB . Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 2000; 163: 460–463.

    Article  CAS  Google Scholar 

  3. Moreira Jr ED, Lbo CF, Diament A, Nicolosi A, Glasser DB . Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology 2003; 61: 431–436.

    Article  Google Scholar 

  4. Shiri R, Koskimaki J, Hakama M, Hakkinen J, Tammela TL, Huhtala H et al. Effect of chronic diseases on incidence of erectile dysfunction. Urology 2003; 62: 1097–1102.

    Article  Google Scholar 

  5. Shiri R, Hakkinen J, Koskimaki J, Huhtala H, Auvinen A, Hakama M et al. Association between the bothersomeness of lower urinary tract symptoms and the prevalence of erectile dysfunction. J Sex Med 2005; 2: 438–444.

    Article  Google Scholar 

  6. Billups KL, Bank AJ, Padma-Nathan H, Katz S, Williams R . Erectile dysfunction is a marker for cardiovascular disease: results of the minority health institute expert advisory panel. J Sex Med 2005; 2: 40–50; discussion 50–52.

    Article  Google Scholar 

  7. Vallancien G, Emberton M, Harving N, van Moorselaar RJ . Sexual dysfunction in 1274 European men suffering from lower urinary tract symptoms. J Urol 2003; 169: 2257–2261.

    Article  Google Scholar 

  8. Ricci E, Parazzini F, Mirone V, Imbimbo C, Palmieri A, Bortolotti A et al. Current drug use as risk factor for erectile dysfunction: results from an Italian epidemiological study. Int J Impot Res 2003; 15: 221–224.

    Article  CAS  Google Scholar 

  9. Derby CA, Barbour MM, Hume AL, McKinlay JB . Drug therapy and prevalence of erectile dysfunction in the Massachusetts Male Aging Study cohort. Pharmacotherapy 2001; 21: 676–683.

    Article  CAS  Google Scholar 

  10. Srilatha B, Adaikan PG, Arulkumaran S, Ng SC . Sexual dysfunction related to antihypertensive agents: results from the animal model. Int J Impot Res 1999; 11: 107–113.

    Article  CAS  Google Scholar 

  11. Fogari R, Preti P, Derosa G, Marasi G, Zoppi A, Rinaldi A et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 2002; 58: 177–180.

    Article  CAS  Google Scholar 

  12. Dusing R . Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl 2003; 2: 29–34.

    Article  CAS  Google Scholar 

  13. Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L . Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001; 14: 27–31.

    Article  CAS  Google Scholar 

  14. Kifor I, Williams GH, Vickers MA, Sullivan MP, Jodbert P, Dluhy RG . Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 1997; 157: 1920–1925.

    Article  CAS  Google Scholar 

  15. Comiter CV, Sullivan MP, Yalla SV, Kifor I . Effect of angiotensin II on corpus cavernosum smooth muscle in relation to nitric oxide environment: in vitro studies in canines. Int J Impot Res 1997; 9: 135–140.

    Article  CAS  Google Scholar 

  16. Rosen RC, Kostis JB, Jekelis AW . Beta-blocker effects on sexual function in normal males. Arch Sex Behav 1988; 17: 241–255.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Financial support for this study was provided by the Medical Research Fund of Tampere University Hospital.

Author information

Authors and Affiliations

  1. Tampere School of Public Health, University of Tampere, Tampere, Finland

    R Shiri, A Auvinen & M Hakama

  2. Department of Urology, Tampere University Hospital, Tampere, Finland

    J Koskimäki, J Häkkinen & T L J Tammela

  3. Medical School, University of Tampere, Tampere, Finland

    T L J Tammela

Authors
  1. R Shiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Koskimäki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Häkkinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Auvinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T L J Tammela
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Hakama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Shiri.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shiri, R., Koskimäki, J., Häkkinen, J. et al. Cardiovascular drug use and the incidence of erectile dysfunction. Int J Impot Res 19, 208–212 (2007). https://doi.org/10.1038/sj.ijir.3901516

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901516

Keywords

This article is cited by

Search

Advanced search

Quick links